TTD | Drug: D04TQO

Drug General Information
Drug ID	D04TQO
Former ID	DNCL003361
Drug Name	AZD1722
Drug Type	Small molecular drug
Indication	Renal disease [ICD10:N00-N29]		Phase 2	[524182]
Company	AstraZeneca
Structure		Download 2D MOL
Formula	C50H66Cl4N8O10S2
InChI	InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1
InChIKey	DNHPDWGIXIMXSA-CXNSMIOJSA-N
PubChem Compound ID	71587953
PubChem Substance ID	163643268, 198966338, 240221763, 242654674, 252166659
Target and Pathway
Target(s)	Sodium/hydrogen exchanger 3	Target Info	Modulator	[550792]
KEGG Pathway	Proximal tubule bicarbonate reclamation
	Protein digestion and absorption
	Bile secretion
	Mineral absorption
Pathway Interaction Database	Endothelins
Pathway Interaction Database	RhoA signaling pathway
WikiPathways	SIDS Susceptibility Pathways
References
Ref 524182	ClinicalTrials.gov (NCT01764854) Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis. U.S. National Institutes of Health.
Ref 550792	RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit. Gastroenterology. 2011;140(suppl 1):S99.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information